Qyuns Therapeutics Past Earnings Performance
Past criteria checks 0/6
Qyuns Therapeutics's earnings have been declining at an average annual rate of -1.5%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 412.7% per year.
Key information
-1.5%
Earnings growth rate
8.3%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 412.7% |
| Return on equity | -120.9% |
| Net Margin | -706.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Qyuns Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 60 | -422 | 136 | 341 |
| 31 Mar 24 | 37 | -465 | 150 | 353 |
| 31 Dec 23 | 15 | -508 | 165 | 364 |
| 30 Sep 23 | 13 | -476 | 167 | 331 |
| 31 Dec 22 | 10 | -298 | 77 | 257 |
| 31 Dec 21 | 21 | -298 | 49 | 152 |
Quality Earnings: 2509 is currently unprofitable.
Growing Profit Margin: 2509 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2509's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2509's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2509 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.4%).
Return on Equity
High ROE: 2509 has a negative Return on Equity (-120.94%), as it is currently unprofitable.